Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation
Issued Date
2022-09-26
Resource Type
eISSN
23078960
Scopus ID
2-s2.0-85138593043
Journal Title
World Journal of Clinical Cases
Volume
10
Issue
27
Start Page
9588
End Page
9601
Rights Holder(s)
SCOPUS
Bibliographic Citation
World Journal of Clinical Cases Vol.10 No.27 (2022) , 9588-9601
Suggested Citation
Leowattana W., Leowattana T., Leowattana P. Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation. World Journal of Clinical Cases Vol.10 No.27 (2022) , 9588-9601. 9601. doi:10.12998/wjcc.v10.i27.9588 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85521
Title
Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation
Author(s)
Other Contributor(s)
Abstract
Patient-specific human-induced pluripotent stem cell-derived atrial cardiomyocytes (hiPSC-aCMs) may be produced, genome-edited, and differentiated into multiple cell types for regenerative medicine, disease modeling, drug testing, toxicity screening, and three-dimensional tissue fabrication. There is presently no complete model of atrial fibrillation (AF) available for studying human pharmacological responses and evaluating the toxicity of potential medication candidates. It has been demonstrated that hiPSC-aCMs can replicate the electrophysiological disease phenotype and genotype of AF. The hiPSC-aCMs, however, are immature and do not reflect the maturity of aCMs in the native myocardium. Numerous laboratories utilize a variety of methodologies and procedures to improve and promote aCM maturation, including electrical stimulation, culture duration, biophysical signals, and changes in metabolic variables. This review covers the current methods being explored for use in the maturation of patient-specific hiPSC-aCMs and their application towards a personalized approach to the pharmacologic therapy of AF